Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Claims ABI In Breach of Genotyping Pact

NEW YORK, Dec. 5 - Illumina is claiming that Applied Biosystems is in breach of a joint-development deal the companies penned in 1999 to commercialize a genotyping system.


The notification, made in a statement released early this morning, comes on the heels of a patent-infringement suit that ABI filed against Illumina related to its own oligo-ligation assay. Oh, and ABI alleges Illumina breached the contract, and is seeking arbitration.


"We are deeply disappointed that after [ABI's] failure to achieve its development responsibilities under the agreement, they have decided to sue their partner, without any attempt to contact us before filing, in an effort to restrain us from selling our independently developed system," Jay Flatley, Illumina's president and CEO, said in the statement. ABI's case "is without merit and we plan to vigorously defend the company and its products."


Illumina announced in July that ABI would be unable to meet the planned mid-year product launch of the new system, the company said. This delay followed an earlier one by the Applera unit, this one from the partners' initial launch date of December 2001.


"The Joint Development Agreement has passed its third anniversary without release of a collaboration product, yet Illumina continues to have no information on when or if ABG will complete its development effort," Illumina said in the statement.


Added Flatley: "Despite ABI's delays and litigation tactics, we stand ready to fulfill our obligations under the JDA."


Officials from ABI were not immediately available for comment.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.